Moderna Covid-19 vaccine gets Phase 2 study green light

Moderna Covid-19 vaccine gets Phase 2 study green light

PanARMENIAN.Net - The promising coronavirus vaccine developed by Cambridge-based company Moderna was cleared by the FDA for a phase 2 study, a step that will push the much needed vaccine forward, Boston Herald reports.

Moderna Therapeutics, a Cambridge, Mass.-based biotech company co-founded by Armenian entrepreneur Noubar Afeyan, shipped the first batches of its Covid-19 vaccine in February.

“The imminent Phase 2 study start is a crucial step forward as we continue to advance the clinical development of mRNA-1273, our vaccine candidate against SARS-CoV-2,” said Stephane Bancel, Moderna’s chief executive officer in a press release issued by the company on Thursday.

Moderna has a goal of starting a pivotal phase 3 study in the summer and could have its first biologics license application approved as soon as next year, Bancel’s statement said.

“We are accelerating manufacturing scale-up and our partnership with Lonza puts us in a position to make and distribute as many vaccine doses of mRNA-1273 as possible, should it prove to be safe and effective,” said Bancel.

 Top stories
Ashot Aharonyan said the police will immediately establish checkpoints on roads connecting to Artsakh.
The vaccine was created just 42 days after the genetic sequence of the COVID_19 virus was released.
Ewa succumbed to RS while her family were trying for asylum in Sweden and threatened with deportation to Poland.
Aliyev said the conflict "should be resolved within international law, According to which Karabakh is part of Azerbaijan."
Partner news